Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
Provided By GlobeNewswire
Last update: Mar 4, 2025
Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history
Read more at globenewswire.com0.33
+0 (+0.3%)
Find more stocks in the Stock Screener
PASG Latest News and Analysis
17 days ago - ChartmillThe market is filled with gapping stocks in Thursday's session.There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
